.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,399,485

« Back to Dashboard

Claims for Patent: 7,399,485

Title:Rapidly Disintegrable solid preparation
Abstract:A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.
Inventor(s): Shimizu; Toshihiro (Itami, JP), Sugaya; Masae (Ikeda, JP), Nakano; Yoshinori (Takarazuka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:09/403,429
Patent Claims: 1. A method for preparing a rapidly disintegrable tablet comprising producing fine granules containing lansoprazole, said granules having a core and at least one layer coating said core, blending said fine granules with a sugar and a low-substituted hydroxypropylcellulose having 5% to less than 7% by weight of hydroxypropoxyl groups, said sugar is an amount of in an amount of 5 to 97 parts by weigh per 100 parts by weight of the rest of the tablet other than the fine granules and molding to obtain a tablet, wherein said tablet is bucally dissolved in from about 5 to about 50 seconds.

2. A method for improving fast disintegrability of a lansoprazole comprising adding low-substituted hydroxypropylcellulose having 5% to less than 7% by weight of hydroxypropoxyl groups and sugar in combination with fine granules containing lansoprazole to obtain an improved tablet; wherein said sugar is added in an amount of 5 to 97 parts by weight per 100 parts by weight of the rest of the tablet other than said fine granules, and wherein said improved tablet is bucally dissolved in from about 5 to about 50 seconds.

3. The method of claim 1, wherein said tablet is bucally dissolved in from about 5 to about 40 seconds.

4. The method of claim 1, wherein said tablet is bucally dissolved in from about 5 to about 35 seconds.

5. The method of claim 1, wherein said sugar is a sugar alcohol.

6. The method of claim 1, wherein said sugar is mannitol or erythritol.

7. The method of claim 2, wherein said tablet is bucally dissolved in from about 5 to about 40 seconds.

8. The method of claim 2, wherein said tablet is bucally dissolved in from about 5 to about 35 seconds.

9. An orally disintegrabic tablet comprising: fine granules containing lansoprazole, said granules having a core and at least one layer coating said core; a sugar wherein said sugar is in an amount of 5 to 97 parts by weight of the rest of the tablet other than said fine granules; and a low-substituted hydroxypropylcellulose having 5 to 7% by weight of hydroxypropoxyl groups; wherein said low-substituted hydroxypropyl cellulose is separate from said fine granules in said tablet; wherein said tablet is improved in chalky taste and has no roughness and wherein said tablet is bucally dissolved in from about 5 to about 50 seconds.

10. The tablet of claim 9 wherein said fine granules are enteric-coated fine granules.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc